牛唐2021-03-31 09:44
$灿菲特生物制药(CANF)$ 的药物Piclidenoson和Namodenoson在现有的六份分销协议中,剩余的潜在里程碑付款高达约1.3亿美元,外加两位数的净销售额分成。$新泰医药(MDGL)$ $泰格医药(SZ300347)$查看全文
$CAN-FITE BIOPHARMA LTD(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2017-02-28 AccNo: 0001213900-17-001821 Size: 39 KB 网页链接
$CAN-FITE BIOPHARMA LTD(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2017-02-08 AccNo: 0001213900-17-001068 Size: 36 KB 网页链接
$CAN-FITE BIOPHARMA LTD(CANF)$ D - Notice of Exempt Offering of Securities Filed: 2017-01-25 AccNo: 0001213900-17-000661 Size: 12 KB 网页链接
$CAN-FITE BIOPHARMA LTD(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2017-01-20 AccNo: 0001213900-17-000539 Size: 547 KB 网页链接
$CAN-FITE BIOPHARMA LTD(CANF)$ 424B5 - Prospectus [Rule 424(b)(5)] Filed: 2017-01-20 AccNo: 0001213900-17-000537 Size: 1 MB 网页链接
$CAN-FITE BIOPHARMA LTD(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2017-01-19 AccNo: 0001213900-17-000488 Size: 18 KB 网页链接
$CAN-FITE BIOPHARMA LTD(CANF)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2017-01-19 AccNo: 0001213900-17-000468 Size: 30 KB 网页链接
$CAN-FITE BIOPHARMA LTD(CANF)$ 美东时间 2014-01-14 18:30 Can Fite Biopharma Ltd at EBD Biotech Showcase 网页链接